OS Therapies OSTX Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $7.35M+462% | $8.8M+911% | $3.76M+210% | $2.5M+530% | $1.31M+262% | ||
| $2.82M-23.7% | $3.19M+52.3% | $3.12M+155% | $2.34M+510% | $3.69M+1,275% | ||
| -$10.17M-103% | -$11.99M-304% | -$6.88M-182% | -$4.84M-521% | -$5M-693% | ||
| $75.34K— | —— | —— | —— | —— | ||
| -$228.89K-120% | -$1.47M-5,837% | $65+100% | $302.11K+139% | $1.12M+235% | ||
| 50%0.0% | 50%0.0% | —— | —— | 50%0.0% | ||
| -$10.4M-168% | -$13.46M-350% | -$6.88M-139% | -$4.54M-191% | -$3.88M-166% | ||
| -$0.27-50.0% | -$0.41+35.9% | -$0.21-16.7% | -$0.19+26.9% | -$0.18+28.0% | ||
| -$10.04M-101% | -$11.86M-300% | -$6.75M-177% | -$4.73M-507% | -$5M-694% | ||
| -$10.17M-103% | -$11.99M-304% | -$6.88M-182% | -$4.84M-521% | -$5M-693% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is OS Therapies profitable?
- OS Therapies is not currently profitable: it reported a net loss of $35.3M over the trailing twelve months.
- What is OS Therapies's earnings per share?
- OS Therapies's diluted EPS over the trailing twelve months is $-1.08.
- Where does OS Therapies's income statement data come from?
- Every line is extracted from OS Therapies's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.